PharmiWeb.com - Global Pharma News & Resources

Clinical research - Press Releases

Date Title Company
05-Jun-2024 Quell Therapeutics Advances QEL-001, its Multi-modular Engineered CAR-Treg Cell Therapy, into Efficacy Cohort of LIBERATE Phase 1/2 Trial in Liver Transplant Patients Quell Therapeutics
05-Jun-2024 OncoZenge participates in MASCC cancer care conference June 27-29 OncoZenge
05-Jun-2024 Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine Valneva SE
05-Jun-2024 Grey Wolf Therapeutics Presents First Clinical Data for GRWD5769, a First-in-Class ERAP1 Inhibitor, at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting Grey Wolf Therapeutics
05-Jun-2024 Otsuka announces new results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in people with hereditary angioedema Otsuka Pharmaceutical Europe Ltd.
05-Jun-2024 Aragen Bioscience Validates Getinge's Single-Use Production Reactor (SUPR) Aragen
05-Jun-2024 OncoHost Announces New Study on Biomarkers for Renal Cell Carcinoma OncoHost
05-Jun-2024 ENCOURAGING NEW DATA PRESENTED ON KITE’S YESCARTA (AXICABTAGENE CILOLECUEL) FOR RELAPSED/REFRACTORY CENTRAL NERVOUS SYSTEM LYMPHOMA Kite, a Gilead Company
05-Jun-2024 Brandon Capital Announces Sixth Fund with A$270 million (US$180 million) Initial Close to Drive Life Science Innovation Brandon Capital
05-Jun-2024 invoX Pharma Presents Positive Clinical Data from Phase 1 Study of FS222 in Patients with Advanced Solid Tumours at the 2024 American Society of Clinical Oncology Annual Meeting invoX Pharma
05-Jun-2024 Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Address Current and Emerging Health Threats Shionogi & Co., Ltd
05-Jun-2024 New GVP Training with Certificate Pharma Lessons
03-Jun-2024 ENCOURAGING NEW DATA PRESENTED ON KITE’S YESCARTA (AXICABTAGENE CILOLECUEL) FOR RELAPSED/REFRACTORY CENTRAL NERVOUS SYSTEM LYMPHOMA Kite, a Gilead Company
03-Jun-2024 Lundbeck presents innovative first in human trial design of Lu AG13909 for potential treatment of congenital adrenal hyperplasia H. Lundbeck A/S
03-Jun-2024 Grey Wolf Therapeutics Presents First Clinical Data for GRWD5769, a First-in-Class ERAP1 Inhibitor, at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting Grey Wolf Therapeutics
03-Jun-2024 TMC welcomes Joe Lopez as Chief Financial Officer (CFO) to enhance corporate C-level team TMC Pharma Services Ltd
03-Jun-2024 Qlucore starts project after receiving prestigious EU grant to advance personalized cancer treatment Qlucore
03-Jun-2024 STORM Therapeutics Presented Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024 STORM Therapeutics
03-Jun-2024 HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine HUTCHMED
03-Jun-2024 Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer Transgene